-Clinical data provides conclusive evidence for the treatment of chronic pain and neuropathic pain
-Neuropathic is not well controlled with current treatments
-Adverse effect of opiates include respiratory depression
-Opioid overdose mortality rates reported to be 24.8% lower in US states with medical cannabis laws
-Canadian study showed chronic pain patients had no greater risk than non-users to experience serious adverse events
-Significant reduction in opioid use – 44% to 65% reduction cited
-Cannabinoids and opioids share several pharmacologic properties and may act synergistically
AusCann is initially targeting neuropathic and chronic pain. A combined market opportunity of >$5 billion in Australia alone
Source: Company calculations based upon $5 per day – approx. $1825/yr
25
TARGET MARKETS AND OPPORTUNITY